Target intelligence / Profile preview

Envelope glycoprotein D (gD2)

Target
gD2
Molecular classification
Viral envelope glycoprotein, Viral protein, Other
01

Overview

Envelope glycoprotein D (gD2) is an essential structural component of the Herpes simplex virus type 2 (HSV-2) envelope. It plays a critical role in viral entry and cell-to-cell spread by binding to specific host cell receptors, including nectin-1, nectin-2, and herpesvirus entry mediator (HVEM). This binding event triggers conformational changes in other viral glycoproteins (gB and the gH/gL complex), leading to the fusion of the viral envelope with the host cell membrane. Because of its indispensable role in infectivity and its high immunogenicity, gD2 has been a primary target for the development of prophylactic and therapeutic vaccines, as well as neutralizing monoclonal antibodies. Historically, subunit vaccines targeting gD2 (such as GSK's Simplirix/Herpevac) induced robust neutralizing antibodies but failed to protect against HSV-2 infection in clinical trials, likely due to rapid antibody decline and shielding of gD2 by other viral glycoproteins like gC and gE. Modern therapeutic approaches include monoclonal antibodies like UB-621, which block the gD-receptor interface to prevent viral entry, and next-generation mRNA vaccines (such as BioNTech's BNT163 and Moderna's mRNA-1608) that combine gD2 with other viral antigens to overcome immune evasion and elicit broader, more durable immune responses.

Other names
gD2gD-2US6gp55Herpes simplex virus type 2 glycoprotein DHSV-2 glycoprotein DEnvelope glycoprotein D of HSV-2Human herpesvirus 2 envelope glycoprotein D
02

Mechanism of action

Neutralization of viral entry and cell-to-cell spread by blocking the interaction of glycoprotein D with host cell receptors (such as nectin-1, nectin-2, and herpesvirus entry mediator [HVEM]), thereby preventing viral fusion and infection.

03

Biological functions

Viral entryViral attachment to host cellMembrane fusionHost-virus interactionImmune evasion
04

Disease associations

InfectionGenital herpesNeonatal herpesHerpes simplex virus type 2 infection
05

Safety considerations

Injection site reactionsSystemic reactogenicity (fever, fatigue, headache, myalgia)Risk of immune evasion due to shielding by other viral glycoproteins (such as gC and gE)Potential for low efficacy in preventing HSV-2 infection despite high antibody titers (as seen in historical subunit vaccine trials)
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Anti-gD2 antibody titersHSV-2 neutralizing antibody titersHSV-2 viral loadViral shedding rate

Beyond the preview

Go deeper on Envelope glycoprotein D (gD2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Envelope glycoprotein D (gD2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call